Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

As previously reported, William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform after the company reported Q2 results and cut ...

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-time, ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

CoStar’s second quarter saw solid execution, with revenue and non-GAAP earnings both surpassing Wall Street expectations, ...

Global Industrial Company posts record Q2 2025 performance with 3.2% revenue growth, margin gains, and strategic shifts toward customer-centricity ...

SoFi Technologies shines in Q2 2025 with record revenue, robust member growth, blockchain & crypto innovation, and raised guidance.

Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and ...

After leaving Wall Street's expectations in the dust, the San Francisco-based fintech dialed up its outlook for the rest of 2025. And as regulators warm to crypto, SoFi sees opportunities for years to ...